Abstracts tagged "IMMUNE MEDIATED INFLAMMATORY DISEASES"

Abstract Number: 0198 • ACR Convergence 2021
High Dose Intravenous Methylprednisolone Induces Rapid Improvement of Visual Acuity in Non-Infectious Uveitis of Different Immune Mediated Inflammatory Diseases
Nuria Vegas-Revenga¹, José Luis Martin-Varillas², Vanesa Calvo-Río³, Iñigo Gonzalez-Mazon⁴, Lara Sánchez-Bilbao⁵, Emma Beltrán Catalán⁶, Alejandro Fonollosa⁷, Ana Blanco⁸, Ana Blanco⁹, Miguel Cordero Coma¹⁰, Norberto Ortego¹¹, Ignacio Torre¹², Felix Hernandez¹³, Santiago Muñóz-Fernández¹⁴, Maria del Mar Esteban-Ortega¹⁴, Manuel Diaz-Llopis¹⁵, Joaquin Cañal⁵, Juan Antonio Ventosa⁵, Rosalía Demetrio-Pablo¹⁶, Lucia Cristina Dominguez Casas¹⁷, Santos Castañeda¹⁸, Iván Ferraz-Amaro¹⁹, Miguel Ángel gonzalez-Gay²⁰ and Ricardo Blanco³, ¹Hospital Galdakao, Galdakao, Spain, ²Hospital Sierrallana, Torrelavega, Spain, ³Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴H. U. Marques de Valdecilla, Santander, Spain, ⁵Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁶Hospital del Mar, Barcelona, Spain, ⁷Hospital Universitario de Cruces, Barakaldo, Spain, ⁸Hospital Universitario de Donostia, San Sebastián, ⁹Hospital Universitario de Donostia, Donostia, Spain, ¹⁰Hospital de León, Leon, Spain, ¹¹Medicine Department, Universidad de Granada, Granada, Spain, ¹²Hospital Universitario de Basurto, Bilbao, Spain, ¹³Hospital Doctor Negrín, Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain, ¹⁴Hospital Universitario Infanta Sofia, Madrid, Spain, ¹⁵Hospital Universitario La Fe, Valencia, Spain, ¹⁶Hospital Universitario de Marqués de Valdecilla, Santander, Spain, ¹⁷Hospital Universtario San Agustin, Oviedo, Spain, ¹⁸Hospital Universitario de la Princesa, Madrid, Spain, ¹⁹Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ²⁰Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: Rapid and effective remission-inducing therapy is mandatory in uveitis to avoid irreversible structural and functional damage. In some severe cases biological agents might be…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].